Business · 03/04/2026Updated: 10/16/2026 · 1 min read
Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
Summary
The FDA has determined the regulatory review period for the patent extension of ENFLONSIA, a human biological product, following a submission to the USPTO. The Agency is publishing this notice as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →